Can trimethoprim‑sulfamethoxazole (cotrimoxazole) be used safely in pregnancy, and what dosing and folic‑acid supplementation guidelines should be followed?

Cotrimoxazole in Pregnancy

Cotrimoxazole should be avoided during the first trimester of pregnancy due to potential teratogenic risks, but can be used in the second and third trimesters when clinically necessary with mandatory 5 mg daily folic acid supplementation. 1

Trimester-Specific Recommendations

First Trimester (Avoid)

• Avoid cotrimoxazole during organogenesis (first 12-14 weeks of pregnancy) 1
• Epidemiologic studies suggest associations with:
  • Neural tube defects
  • Cardiovascular abnormalities
  • Urinary tract defects
  • Oral clefts 2, 3
• The teratogenic risk appears related to trimethoprim's antifolate effects interfering with folic acid metabolism 2

Critical caveat: The FDA label 2 notes that some retrospective studies found these associations while others did not detect statistically significant links. The evidence is limited by small sample sizes, recall bias, and lack of adjustment for confounders.

Second and Third Trimesters (Use with Caution)

• Can be used when clinically indicated if safer alternatives are unavailable 1
• The 2020 ERS/TSANZ guidelines 1 classify cotrimoxazole as Category C with recommendation to "Avoid" in first trimester but "Possibly safe" in second/third trimesters
• Mandatory folic acid supplementation: 5 mg daily throughout treatment and especially during third trimester 1

Near Term and Delivery (Special Precautions)

• Avoid use at delivery when possible 1
• Sulfonamide component carries risks:
  • Neonatal hyperbilirubinemia
  • Fetal hemolytic anemia
  • Potential kernicterus (though extremely rare) 1, 2
• If used near term, inform neonatal care team to monitor for hyperbilirubinemia 4

Clinical Context for Use

When Cotrimoxazole May Be Justified

The 2021 CDC plague guidelines 4 provide important context: "For women in the United States with known or suspected pregnancy and Y. pestis infection or exposure, the risk-benefit profile favors the use of trimethoprim-sulfamethoxazole during any trimester." This reflects that in serious infections, the maternal and fetal benefits of treating life-threatening disease outweigh theoretical teratogenic risks.

Similarly, the 2024 pediatric methotrexate consensus 5 states that concomitant use of methotrexate and cotrimoxazole is not contraindicated, indicating the drug can be used when medically necessary despite theoretical concerns.

Folic Acid Supplementation Protocol

• Standard dose: 5 mg daily (not the typical 400 mcg prenatal dose) 1
• Start before cotrimoxazole initiation if possible
• Continue throughout treatment
• Women treated with trimethoprim during first trimester require folic acid supplementation 1
• The 2020 bariatric surgery guidelines 6 recommend 5 mg folic acid for women with BMI >30 or diabetes planning pregnancy, which parallels the higher dose needed with antifolate drugs

Breastfeeding Considerations

• Compatible with breastfeeding in healthy, full-term infants 1
• Cotrimoxazole levels in breast milk are approximately 2-5% of infant therapeutic dose 2
• Contraindications for breastfeeding:
  • Premature infants
  • Jaundiced infants
  • Infants with G6PD deficiency 1, 2
• Risk of kernicterus from bilirubin displacement, though exceedingly rare 2

Alternative Antibiotics in Pregnancy

When cotrimoxazole must be avoided, consider these safer alternatives 1:

• Amoxicillin (Category A/B) - compatible throughout pregnancy
• Cephalosporins (e.g., cefuroxime, Category B1) - compatible throughout pregnancy
• Azithromycin (Category B1) - probably safe, though avoid first 13 days of breastfeeding

Key Clinical Pitfalls

1. Don't forget folic acid supplementation - This is mandatory, not optional, at 5 mg daily (10x the standard prenatal dose)
2. Inform neonatal team - If used in third trimester, ensure pediatricians monitor for hyperbilirubinemia
3. Check G6PD status - Before prescribing to breastfeeding mothers, especially in high-risk populations
4. Document risk-benefit discussion - The FDA label 2 states: "should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus"

Recent Evidence

A 2025 randomized trial 7 in Zimbabwe (993 pregnant women, 131 HIV-positive) found that daily cotrimoxazole prophylaxis from median 21.7 weeks gestation did not significantly increase birth weight (mean difference 20g, 95% CI -43 to 83, p=0.53), with similar adverse event rates between groups. This suggests prophylactic use in second/third trimester does not improve outcomes in unselected populations, though it doesn't address treatment of active infections.

A 2018 nested case-control study 8 found cotrimoxazole exposure associated with increased spontaneous abortion risk (adjusted OR 2.94,95% CI 1.89-4.57), reinforcing first-trimester avoidance.